Last10K.com

La Jolla Pharmaceutical Co (LJPC) SEC Filing 8-K Material Event for the period ending Tuesday, July 28, 2020

La Jolla Pharmaceutical Co

HISTORY TOOLS
CIK: 920465 Ticker: LJPC

View differences made from one to another to evaluate La Jolla Pharmaceutical Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by La Jolla Pharmaceutical Co.

Continue

Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract
Ticker: LJPC
CIK: 920465
Form Type: 8-K Corporate News
Accession Number: 0000920465-20-000119
Submitted to the SEC: Tue Jul 28 2020 5:36:29 PM EST
Accepted by the SEC: Wed Jul 29 2020
Period: Tuesday, July 28, 2020
Industry: Biological Products No Disgnostic Substances
Events:
  1. Change in Assets
  2. Event for Officers
  3. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ljpc/0000920465-20-000119.htm